Dr. Hung is a nephrologist and epidemiologist who serves as an Assistant Professor of Medicine at Vanderbilt University.  She is also the Dialysis Medical Director, both for the outpatient and the inpatient programs, at the Nashville VA.  Dr. Hung obtained her medical degree from the Universidad Central of Venezuela, completed her residency at Albert Einstein College of Medicine, and a nephrology fellowship at the University of California, San Francisco.  Dr. Hung has received several grants/awards from the National Kidney Foundation, National Institute of Health and the Department of Veterans Affairs.

Dr. Hung's research centers on examining the role of inflammation and impaired glucose metabolism in chronic kidney disease and their impact on cardiovascular disease (CVD) and CKD progression. Specifically, Dr. Hung has studied the role of genetic and environmental factors that contribute to inflammation and insulin resistance, developing methods to better classify insulin resistance in patients with kidney disease, and testing interventions that target these derangements that can lead to better outcomes. Dr. Hung also has extensive experience in pharmacoepidemiology using large databases and has published work comparing the effectiveness of established therapies toward diabetes management to prevent incident CKD and delay CKD progression and improve cardiovascular outcomes.

Dr. Hung is serving as a member of the American Society of Nephrology Dialysis Advisory Group (DAG) (2013-2015) and of the National Committee for the Home Dialysis Program for the Veterans Affairs. She is the local principal investigator for the Million Veteran Program, a member of the CKD working group for the VA network for the Systolic Blood Pressure Intervention Trial (SPRINT trial), and is part of the writing group for the Chronic Kidney Disease Care clinical practice guidelines for the VA system. Additionally, she is a section editor in the field of dialysis, nutrition and metabolism for the Journal of Clinical Nephrology, and is also a member of the editorial board for the Journal of Renal Nutrition. Dr. Hung is also Associate Director for the Summer Research Training Program in Kidney Disease (SRTP-KD), which is sponsored by the National Institutes of Health, and teaches evidence-based medicine, epidemiology and genetic epidemiology to medical and graduate students at Vanderbilt.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Considerations and challenges in defining optimal iron utilization in hemodialysis. Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S, Dialysis Advisory Group of the American Society of Nephrology (2015) J Am Soc Nephrol 26(6): 1238-47
    › Primary publication · 25542967 (PubMed) · PMC4446883 (PubMed Central)
  2. Omega-3 fatty acids inhibit the up-regulation of endothelial chemokines in maintenance hemodialysis patients. Hung AM, Booker C, Ellis CD, Siew ED, Graves AJ, Shintani A, Abumrad NN, Himmelfarb J, Ikizler TA (2015) Nephrol Dial Transplant 30(2): 266-74
    › Primary publication · 25204316 (PubMed) · PMC4309191 (PubMed Central)
  3. Laboratory test surveillance following acute kidney injury. Matheny ME, Peterson JF, Eden SK, Hung AM, Speroff T, Abdel-Kader K, Parr SK, Ikizler TA, Siew ED (2014) PLoS One 9(8): e103746
    › Primary publication · 25117447 (PubMed) · PMC4130516 (PubMed Central)
  4. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Murff HJ, Elasy TA, Griffin MR (2014) JAMA 311(22): 2288-96
    › Primary publication · 24915260 (PubMed) · PMC4149288 (PubMed Central)
  5. Blood pressure goals: how low is safe in CKD? Hung AM, Roumie CL (2014) Am J Kidney Dis 63(6): 892-4
    › Primary publication · 24679896 (PubMed)
  6. Administration of IL-1ra improves adiponectin levels in chronic hemodialysis patients. Hung AM, Limkunakul C, Placido JS, Siew ED, Ellis CD, Shintani A, Ikizler TA (2014) J Nephrol 27(6): 681-8
    › Primary publication · 24609887 (PubMed)
  7. Obesity, diabetes and survival in maintenance hemodialysis patients. Deger SM, Ellis CD, Bian A, Shintani A, Ikizler TA, Hung AM (2014) Ren Fail 36(4): 546-51
    › Primary publication · 24467439 (PubMed) · PMC4976601 (PubMed Central)
  8. Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control. Hung AM, Roumie CL, Greevy RA, Liu X, Grijalva CG, Murff HJ, Griffin MR (2013) Pharmacoepidemiol Drug Saf 22(6): 623-31
    › Primary publication · 23592561 (PubMed) · PMC4887572 (PubMed Central)
  9. Insulin resistance and protein metabolism in chronic hemodialysis patients. Deger SM, Sundell MB, Siew ED, Egbert P, Ellis CD, Sha F, Ikizler TA, Hung AM (2013) J Ren Nutr 23(3): e59-66
    › Primary publication · 23194840 (PubMed) · PMC3852904 (PubMed Central)
  10. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, Elasy TA, Griffin MR (2012) Ann Intern Med 157(9): 601-10
    › Primary publication · 23128859 (PubMed) · PMC4667563 (PubMed Central)
  11. A pilot study of active vitamin D administration and insulin resistance in African American patients undergoing chronic hemodialysis. Hung AM, Sundell MB, Plotnikova NE, Bian A, Shintani A, Ellis CD, Siew ED, Ikizler TA (2013) J Ren Nutr 23(3): 185-93
    › Primary publication · 22959781 (PubMed) · PMC3519966 (PubMed Central)
  12. Reweighted Mahalanobis distance matching for cluster-randomized trials with missing data. Greevy RA, Grijalva CG, Roumie CL, Beck C, Hung AM, Murff HJ, Liu X, Griffin MR (2012) Pharmacoepidemiol Drug Saf : 148-54
    › Primary publication · 22552990 (PubMed) · PMC3760213 (PubMed Central)
  13. Initiation of sulfonylureas versus metformin is associated with higher blood pressure at one year. Roumie CL, Liu X, Choma NN, Greevy RA, Hung AM, Grijalva CG, Griffin MR (2012) Pharmacoepidemiol Drug Saf 21(5): 515-23
    › Primary publication · 22431419 (PubMed) · PMC4667555 (PubMed Central)
  14. Estimating baseline kidney function in hospitalized patients with impaired kidney function. Siew ED, Ikizler TA, Matheny ME, Shi Y, Schildcrout JS, Danciu I, Dwyer JP, Srichai M, Hung AM, Smith JP, Peterson JF (2012) Clin J Am Soc Nephrol 7(5): 712-9
    › Primary publication · 22422536 (PubMed) · PMC3338282 (PubMed Central)
  15. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Hung AM, Roumie CL, Greevy RA, Liu X, Grijalva CG, Murff HJ, Ikizler TA, Griffin MR (2012) Kidney Int 81(7): 698-706
    › Primary publication · 22258320 (PubMed) · PMC3306005 (PubMed Central)
  16. Novel dialysis modalities: do we need new metrics to optimize treatment? Fissell R, Schulman G, Pfister M, Zhang L, Hung AM (2012) J Clin Pharmacol 52(1 Suppl): 72S-8S
    › Primary publication · 22232756 (PubMed)
  17. Outpatient nephrology referral rates after acute kidney injury. Siew ED, Peterson JF, Eden SK, Hung AM, Speroff T, Ikizler TA, Matheny ME (2012) J Am Soc Nephrol 23(2): 305-12
    › Primary publication · 22158435 (PubMed) · PMC3269178 (PubMed Central)
  18. The initial vascular access type contributes to inflammation in incident hemodialysis patients. Sachdeva M, Hung A, Kovalchuk O, Bitzer M, Mokrzycki MH (2012) Int J Nephrol : 917465
    › Primary publication · 22121485 (PubMed) · PMC3202132 (PubMed Central)
  19. Factors determining insulin resistance in chronic hemodialysis patients. Hung AM, Ikizler TA (2011) Contrib Nephrol : 127-134
    › Primary publication · 21625101 (PubMed)
  20. CRP polymorphisms and chronic kidney disease in the third national health and nutrition examination survey. Hung AM, Ikizler TA, Griffin MR, Glenn K, Greevy RA, Grijalva CG, Siew ED, Crawford DC (2011) BMC Med Genet : 65
    › Primary publication · 21569369 (PubMed) · PMC3119179 (PubMed Central)
  21. A comparison of novel and commonly-used indices of insulin sensitivity in African American chronic hemodialysis patients. Hung AM, Sundell MB, Egbert P, Siew ED, Shintani A, Ellis CD, Bian A, Ikizler TA (2011) Clin J Am Soc Nephrol 6(4): 767-74
    › Primary publication · 21441124 (PubMed) · PMC3069368 (PubMed Central)
  22. IL-1β receptor antagonist reduces inflammation in hemodialysis patients. Hung AM, Ellis CD, Shintani A, Booker C, Ikizler TA (2011) J Am Soc Nephrol 22(3): 437-42
    › Primary publication · 21310819 (PubMed) · PMC3060437 (PubMed Central)
  23. The effect of incident antidiabetic regimens on lipid profiles in veterans with type 2 diabetes: a retrospective cohort. Roumie CL, Huizinga MM, Liu X, Greevy RA, Grijalva CG, Murff HJ, Hung AM, Griffin MR (2011) Pharmacoepidemiol Drug Saf 20(1): 36-44
    › Primary publication · 21182152 (PubMed)
  24. Glycemic and weight changes after persistent use of incident oral diabetes therapy: a Veterans Administration retrospective cohort study. Huizinga MM, Roumie CL, Greevy RA, Liu X, Murff HJ, Hung AM, Grijalva CG, Griffin MR (2010) Pharmacoepidemiol Drug Saf 19(11): 1108-12
    › Primary publication · 20878643 (PubMed)
  25. CRP polymorphisms and progression of chronic kidney disease in African Americans. Hung AM, Crawford DC, Griffin MR, Brown-Gentry K, Lipkowitz MS, Siew ED, Cavanaugh K, Lewis JB, Ikizler TA, AASK Study Group (2010) Clin J Am Soc Nephrol 5(1): 24-33
    › Primary publication · 19965533 (PubMed) · PMC2801650 (PubMed Central)
  26. The decline in residual renal function in hemodialysis is slow and age dependent. Hung AM, Young BS, Chertow GM (2003) Hemodial Int 7(1): 17-22
    › Primary publication · 19379338 (PubMed)
  27. Associations of interleukin-6, C-reactive protein and serum amyloid A with mortality in haemodialysis patients. Wetmore JB, Lovett DH, Hung AM, Cook-Wiens G, Mahnken JD, Sen S, Johansen KL (2008) Nephrology (Carlton) 13(7): 593-600
    › Primary publication · 18826487 (PubMed) · PMC3375899 (PubMed Central)
  28. Hemodialysis central venous catheters as a source of inflammation and its implications. Hung AM, Ikizler TA (2008) Semin Dial 21(5): 401-4
    › Primary publication · 18573135 (PubMed)
  29. Determinants of C-reactive protein in chronic hemodialysis patients: relevance of dialysis catheter utilization. Hung A, Pupim L, Yu C, Shintani A, Siew E, Ayus C, Hakim RM, Ikizler TA (2008) Hemodial Int 12(2): 236-43
    › Primary publication · 18394058 (PubMed)
  30. An angiotensin converting enzyme haplotype predicts survival in patients with end stage renal disease. Wetmore JB, Johansen KL, Sen S, Hung AM, Lovett DH (2006) Hum Genet 120(2): 201-10
    › Primary publication · 16791616 (PubMed)
  31. Interleukin-1 gene cluster polymorphisms predict risk of ESRD. Wetmore JB, Hung AM, Lovett DH, Sen S, Quershy O, Johansen KL (2005) Kidney Int 68(1): 278-84
    › Primary publication · 15954918 (PubMed)
  32. Inflammatory markers are unrelated to physical activity, performance, and functioning in hemodialysis. Hung AM, Chertow GM, Young BS, Carey S, Johansen KL (2003) Adv Ren Replace Ther 10(3): 232-40
    › Primary publication · 14708079 (PubMed)
  33. Longitudinal study of nutritional status, body composition, and physical function in hemodialysis patients. Johansen KL, Kaysen GA, Young BS, Hung AM, da Silva M, Chertow GM (2003) Am J Clin Nutr 77(4): 842-6
    › Primary publication · 12663281 (PubMed)
  34. Inflammatory markers are unrelated to physical activity, performance, and functioning in hemodialysis. Hung AM, Chertow GM, Young BS, Carey S, Johansen KL (2002) J Ren Nutr 12(3): 170-6
    › Primary publication · 12105814 (PubMed)